Video released of rapid Alzheimer's improvement after new immune-based treatment

July 21, 2008

New research into the treatment of Alzheimer's disease reports improvement in language abilities using a novel immune-based approach. A video accompanying the research, published today in the open access journal BMC Neurology, documents rapid language improvement within minutes of using this new treatment.

Building on previous work by the same authors, published in BioMed Central's Journal of Neuroinflammation, this study focuses on the effect of the anti-tumor necrosis factor–alpha (TNF-alpha) drug, etanercept, on measures of verbal ability.

TNF-alpha, a critical component of the brain's immune system, normally finely regulates the transmission of neural impulses in the brain. The authors hypothesize that elevated levels of TNF-alpha in Alzheimer's disease interfere with this regulation. To reduce elevated TNF-alpha, the authors utilized a unique perispinal delivery method to administer etanercept.

The new BMC Neurology article provides preliminary evidence that the disrupted neural communication seen in Alzheimer's disease may be reversible.

According to the lead author of the study, Edward Tobinick, "There are limitations to the data presented; the clinical trial was open label, and not controlled. These caveats notwithstanding, the scientific rationale for the further investigation of anti-TNF-alpha treatment of Alzheimer's disease is compelling. In addition, family members, independent neurologists, and other independent observers have confirmed the clinical, cognitive, and behavioral improvement noted".

Disruption of language function, such as the ability to find words, is a common symptom in advancing Alzheimer's disease, and this BMC Neurology article is one of the first to suggest the possibility of a new therapeutic approach that may address these symptoms.

The video is available at: w02.biomedcentral.com/download/pr/PPA1280.mov

Article available at journal website: www.biomedcentral.com/bmcneurol/

Source: BioMed Central

Explore further: Early signs of Alzheimer's disease identified

Related Stories

Recommended for you

Artificial beta cells

December 8, 2016

Researchers led by ETH Professor Martin Fussenegger at the Department of Biosystems Science and Engineering (D-BSSE) in Basel have produced artificial beta cells using a straightforward engineering approach.

Key regulator of bone development identified

December 8, 2016

Loss of a key protein leads to defects in skeletal development including reduced bone density and a shortening of the fingers and toes—a condition known as brachydactyly. The discovery was made by researchers at Penn State ...

Researchers question lifelong immunity to toxoplasmosis

December 8, 2016

Medical students are taught that once infected with Toxoplasma gondii—the "cat parasite"—then you're protected from reinfection for the rest of your life. This dogma should be questioned, argue researchers in an Opinion ...

TET proteins drive early neurogenesis

December 7, 2016

The fate of stem cells is determined by series of choices that sequentially narrow their available options until stem cells' offspring have found their station and purpose in the body. Their decisions are guided in part by ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.